Concurrent whole brain radiotherapy and RRx-001 for melanoma brain metastases

Neuro Oncol. 2016 Mar;18(3):455-6. doi: 10.1093/neuonc/nov317. Epub 2016 Jan 13.

Authors

Michelle M Kim¹, Hemant Parmar¹, Yue Cao¹, Susan J Knox¹, Bryan Oronsky¹, Jan Scicinski¹, Theodore S Lawrence¹, Christopher D Lao¹

Affiliation

¹ University of Michigan, Ann Arbor, Michigan (M.M.K., H.P., Y.C., T.S.L., C.D.L.); Stanford University School of Medicine, Radiation Oncology, Stanford, California (S.J.K.); EpicentRx, Inc, Mountain View, California (B.O., J.S.).

No abstract available

Keywords: brain metastases; melanoma; radioresistance; radiosensitizer; whole brain radiotherapy.

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Azetidines / therapeutic use*
Brain Neoplasms / radiotherapy*
Brain Neoplasms / secondary
Humans
Melanoma / radiotherapy*
Melanoma / secondary
Nitro Compounds / therapeutic use*
Treatment Outcome

Substances

Azetidines
Nitro Compounds
RRx-001